PATENT CLAIM ANALYSIS

Application Number: 16073027
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-02
Patent Classification: ["514", "265100"]

Abstract:
A pyrrolopyrimidine five-membered azacyclic derivative as a novel JAK kinase (Janus kinase) inhibitor, and use thereof in a preparation of a pharmaceutical product for preventing and/or treating an indication related to a JAK kinase function. The pyrrolopyrimidine five-membered azacyclic derivative is an ideal JAK kinase inhibitor with a high potency, and can be used to treat or prevent diseases such as rheumatoid arthritis, polycythemia vera, psoriasis, primary thrombocytosis, myelofibrosis, and the like.

Claim (Index 6):
The pyrrolopyrimidine five-membered azacyclic derivative, the pharmaceutically acceptable salt and hydrate thereof, or metabolite metabolized in any form according to  claim 1 , wherein, in formula (I), R 3  is SO 2 CH 2 CH 3 .

Metadata:
- Claim Count in Document: 24.0
- Percentile: 95.0
- Lexical Diversity: 1.45614
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15536648', '10524204', '14000312', '15719867', '16311979']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7959400459341814
- 35 USC 102 Novelty (BERT): 0.4840758080755424
- Combined Prediction Score: 0.7647536221483175
- Mean Citation Score: 236.689044
- Max Citation Score: 238.28767
- Similarity Product: 206.3813518312126

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test